In Vivo Data Spotlight

During Q2, biopharmas brought in an aggregate $22.8bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.2m.

J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.

An interactive look at pharma, medtech and diagnostics deals made during June 2024. Data courtesy of Biomedtracker.

Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma. 

Four $1bn+ alliances were penned in June. In the top alliance by deal value, Ascidian Therapeutics signed an agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases. Roche received exclusive rights to Ascidian's RNA exon editing technology for undisclosed targets. Ascidian will conduct discovery and certain preclinical activities in collaboration with Roche, which will be responsible for certain preclinical activities, and further clinical development, manufacturing, and commercialization. Ascidian will receive an up-front payment of $42m as well as up to $1.8bn in research, clinical, and commercial milestone payments, as well as sales royalties.

Stefan Woxström, senior vice president of AstraZeneca, Europe and Canada, discusses the growing challenges in the industry and addresses the role big pharma must adopt in resolving them.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Dominated by Xaira Therapeutics' $1bn venture financing, Q2 2024 was also notable for sizeable public offerings by Alumis and Recursion Therapeutics in the US and XtalPi Technology in Hong Kong, as well as a $142m seed round for EvolutionaryScale.   

Six $1bn+ alliances were penned in May. In the top alliance by deal value, AC Immune SA granted Takeda an option to license exclusive global rights to active immunotherapies targeting toxic forms of amyloid beta, including ACI-24.060 for the treatment of Alzheimer’s disease. AC Immune will receive $100m up front and is eligible to receive an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1bn, plus sales royalties.

An interactive look at pharma, medtech and diagnostics deals made during May 2024. Data courtesy of Biomedtracker.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Astellas Pharma’s chief commercial officer discusses the biopharma industry’s responsibility to drive change in health care.

Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.

In this episode of the In Vivo podcast, Hakim Yadi, CEO and co-founder of UK techbio Closed Loop Medicine, discusses how the company is pairing software and predictive analytics with medications old and new to tailor drug dosing.  

Seven $1bn+ alliances were penned in April. In the top alliance by deal value, Medincell entered a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will receive a $35m upfront payment and is eligible to receive up to $1.9bn in development and commercial milestones, plus mid-single to low-double-digit royalties on net sales.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.